Do analysts rate CPIX or NNVC?

NanoViricides has a consensus target price of $6.00, suggesting a potential upside of 421.74%. Given NanoViricides' stronger consensus rating and higher possible upside, analysts clearly believe NanoViricides is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media favor CPIX or NNVC?

In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 1 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.59 beat Cumberland Pharmaceuticals' score of 0.37 indicating that NanoViricides is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NanoViricides 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RFL or NNVC?

NanoViricides has a consensus price target of $6.00, suggesting a potential upside of 421.74%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts plainly believe NanoViricides is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is RFL or NNVC more profitable?

NanoViricides has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets Rafael -3,321.74% -41.27% -35.32% NanoViricides N/A -87.90% -78.69%

Which has preferable valuation & earnings, NNVC or PYPD?

PolyPid is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.43 N/A PolyPid N/A N/A -$34.17M -$1.48 N/A

Is NNVC or PYPD more profitable?

NanoViricides' return on equity of -87.90% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% PolyPid N/A -311.08% -150.83%

Does the media prefer NNVC or PYPD?

In the previous week, NanoViricides and NanoViricides both had 1 articles in the media. PolyPid's average media sentiment score of 1.83 beat NanoViricides' score of 0.59 indicating that PolyPid is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PolyPid 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation & earnings, NNVC or CGTX?

Cognition Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.43 N/A Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A

Is NNVC or CGTX more profitable?

Cognition Therapeutics' return on equity of -50.17% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Cognition Therapeutics N/A -50.17% -40.22%

Does the media prefer NNVC or CGTX?

In the previous week, NanoViricides and NanoViricides both had 1 articles in the media. NanoViricides' average media sentiment score of 0.59 beat Cognition Therapeutics' score of 0.00 indicating that NanoViricides is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NanoViricides (NNVC) Competitors

$1.15 -0.02 (-1.71%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$1.14 0.00 (-0.43%)

As of 04:00 AM Eastern

Compare

NNVC vs. CPIX, RFL, FBIO, PYPD, and CGTX

Should you buy NanoViricides stock or one of its competitors? NanoViricides's main competitors and comparable companies include Cumberland Pharmaceuticals (CPIX), Rafael (RFL), Fortress Biotech (FBIO), PolyPid (PYPD), and Cognition Therapeutics (CGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NanoViricides compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and NanoViricides (NYSE:NNVC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

NanoViricides has a consensus target price of $6.00, suggesting a potential upside of 421.74%. Given NanoViricides' stronger consensus rating and higher possible upside, analysts clearly believe NanoViricides is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cumberland Pharmaceuticals has a beta of 0.13, indicating that its stock price is 87% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

NanoViricides has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
NanoViricides	N/A	-87.90%	-78.69%

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 1 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.59 beat Cumberland Pharmaceuticals' score of 0.37 indicating that NanoViricides is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NanoViricides	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cumberland Pharmaceuticals has higher revenue and earnings than NanoViricides. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.27	-$2.84M	-$0.71	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Summary

NanoViricides beats Cumberland Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does NanoViricides compare to Rafael?

Rafael (NYSE:RFL) and NanoViricides (NYSE:NNVC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

NanoViricides has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
NanoViricides	N/A	-87.90%	-78.69%

NanoViricides has lower revenue, but higher earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	141.30	-$30.52M	-$0.68	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

NanoViricides has a consensus price target of $6.00, suggesting a potential upside of 421.74%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts plainly believe NanoViricides is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, NanoViricides had 1 more articles in the media than Rafael. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for Rafael. NanoViricides' average media sentiment score of 0.59 beat Rafael's score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media.

Company	Overall Sentiment
Rafael	Neutral
NanoViricides	Positive

Rafael has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

11.3% of Rafael shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 32.9% of Rafael shares are held by insiders. Comparatively, 3.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

NanoViricides beats Rafael on 10 of the 15 factors compared between the two stocks.

How does NanoViricides compare to Fortress Biotech?

NanoViricides (NYSE:NNVC) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

NanoViricides currently has a consensus price target of $6.00, suggesting a potential upside of 421.74%. Fortress Biotech has a consensus price target of $17.00, suggesting a potential upside of 527.31%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Fortress Biotech has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Fortress Biotech	$68.47M	1.32	$6.82M	$2.64	1.03

Fortress Biotech has a net margin of 163.32% compared to NanoViricides' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Fortress Biotech	163.32%	83.47%	42.98%

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 3.6% of NanoViricides shares are held by insiders. Comparatively, 28.5% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, NanoViricides had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for Fortress Biotech. NanoViricides' average media sentiment score of 0.59 beat Fortress Biotech's score of 0.00 indicating that NanoViricides is being referred to more favorably in the media.

Company	Overall Sentiment
NanoViricides	Positive
Fortress Biotech	Neutral

NanoViricides has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Summary

Fortress Biotech beats NanoViricides on 10 of the 14 factors compared between the two stocks.

How does NanoViricides compare to PolyPid?

NanoViricides (NYSE:NNVC) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

PolyPid is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A

NanoViricides currently has a consensus target price of $6.00, suggesting a potential upside of 421.74%. PolyPid has a consensus target price of $11.33, suggesting a potential upside of 115.05%. Given NanoViricides' stronger consensus rating and higher probable upside, equities analysts plainly believe NanoViricides is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

NanoViricides' return on equity of -87.90% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
PolyPid	N/A	-311.08%	-150.83%

NanoViricides has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, NanoViricides and NanoViricides both had 1 articles in the media. PolyPid's average media sentiment score of 1.83 beat NanoViricides' score of 0.59 indicating that PolyPid is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PolyPid	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

NanoViricides beats PolyPid on 8 of the 12 factors compared between the two stocks.

How does NanoViricides compare to Cognition Therapeutics?

NanoViricides (NYSE:NNVC) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NanoViricides has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Cognition Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

Cognition Therapeutics' return on equity of -50.17% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Cognition Therapeutics	N/A	-50.17%	-40.22%

In the previous week, NanoViricides and NanoViricides both had 1 articles in the media. NanoViricides' average media sentiment score of 0.59 beat Cognition Therapeutics' score of 0.00 indicating that NanoViricides is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NanoViricides currently has a consensus target price of $6.00, suggesting a potential upside of 421.74%. Cognition Therapeutics has a consensus target price of $3.33, suggesting a potential upside of 217.46%. Given NanoViricides' stronger consensus rating and higher possible upside, equities research analysts clearly believe NanoViricides is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cognition Therapeutics beats NanoViricides on 7 of the 12 factors compared between the two stocks.

Get NanoViricides News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNVC vs. The Competition

Export

Metric	NanoViricides	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$29.36M	$12.25B	$7.26B	$23.50B
Dividend Yield	N/A	2.59%	2.53%	3.73%
P/E Ratio	-1.60	787.27	273.29	29.39
Price / Sales	N/A	754.88	623.67	20.98
Price / Cash	N/A	94.80	77.82	32.15
Price / Book	1.74	12.33	12.92	7.63
Net Income	-$8.29M	$2.82B	$3.47B	$1.07B
7 Day Performance	-7.26%	2.60%	0.60%	-0.16%
1 Month Performance	-24.34%	6.96%	5.72%	-0.46%
1 Year Performance	-16.36%	9.45%	25.33%	13.09%

NanoViricides Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
NNVC NanoViricides	1.5908 of 5 stars	$1.15 -1.7%	$6.00 +421.7%	-19.6%	$29.36M	N/A	N/A	20
CPIX Cumberland Pharmaceuticals	0.7262 of 5 stars	$8.70 +11.0%	N/A	+87.0%	$117.47M	$44.52M	N/A	80
RFL Rafael	0.1239 of 5 stars	$2.26 +3.0%	N/A	+67.2%	$113.88M	$920K	N/A	20
FBIO Fortress Biotech	2.4387 of 5 stars	$2.83 -3.4%	$17.00 +500.7%	-8.1%	$97.72M	$63.26M	1.07	170
PYPD PolyPid	3.2373 of 5 stars	$5.10 +2.2%	$11.33 +122.2%	+54.1%	$95.13M	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NNVC) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NanoViricides (NNVC) Competitors

NNVC vs. CPIX, RFL, FBIO, PYPD, and CGTX

How does NanoViricides compare to Cumberland Pharmaceuticals?

Summary

How does NanoViricides compare to Rafael?

Summary

How does NanoViricides compare to Fortress Biotech?

Summary

How does NanoViricides compare to PolyPid?

Summary

How does NanoViricides compare to Cognition Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NanoViricides (NNVC) Competitors

NNVC vs. CPIX, RFL, FBIO, PYPD, and CGTX

How does NanoViricides compare to Cumberland Pharmaceuticals?

Do analysts rate CPIX or NNVC?

Which has more risk and volatility, CPIX or NNVC?

Is CPIX or NNVC more profitable?

Do insiders & institutionals hold more shares of CPIX or NNVC?

Does the media favor CPIX or NNVC?

Which has stronger earnings & valuation, CPIX or NNVC?

Summary

How does NanoViricides compare to Rafael?

Is RFL or NNVC more profitable?

Which has higher valuation & earnings, RFL or NNVC?

Do analysts rate RFL or NNVC?

Does the media favor RFL or NNVC?

Which has more risk & volatility, RFL or NNVC?

Do insiders and institutionals hold more shares of RFL or NNVC?

Summary

How does NanoViricides compare to Fortress Biotech?

Do analysts rate NNVC or FBIO?

Which has stronger valuation and earnings, NNVC or FBIO?

Is NNVC or FBIO more profitable?

Do institutionals & insiders believe in NNVC or FBIO?

Does the media prefer NNVC or FBIO?

Which has more volatility & risk, NNVC or FBIO?

Summary

How does NanoViricides compare to PolyPid?

Which has preferable valuation & earnings, NNVC or PYPD?

Do analysts recommend NNVC or PYPD?

Is NNVC or PYPD more profitable?

Which has more risk & volatility, NNVC or PYPD?

Do insiders and institutionals believe in NNVC or PYPD?

Does the media prefer NNVC or PYPD?

Summary

How does NanoViricides compare to Cognition Therapeutics?

Do institutionals and insiders believe in NNVC or CGTX?

Which has more risk & volatility, NNVC or CGTX?

Which has stronger valuation & earnings, NNVC or CGTX?

Is NNVC or CGTX more profitable?

Does the media prefer NNVC or CGTX?

Do analysts rate NNVC or CGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools